AI Tokens
Stock Analysis on Net

Thermo Fisher Scientific Inc. (NYSE:TMO)

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Turnover Ratios

Average No. Days

Thermo Fisher Scientific Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Turnover Ratios
Inventory turnover 4.94 4.87 4.87 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Receivables turnover 4.92 4.90 4.91 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Payables turnover 9.04 8.39 8.00 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Working capital turnover 4.14 5.59 5.87 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Average No. Days
Average inventory processing period 74 75 75 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Add: Average receivable collection period 74 74 74 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Operating cycle 148 149 149 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Less: Average payables payment period 40 43 46 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Cash conversion cycle 108 106 103 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).


The operational activity ratios indicate a general improvement in inventory efficiency over the analyzed period, though this is offset by a slight deterioration in receivables collection and significant volatility in working capital utilization.

Inventory Management
Inventory turnover exhibited a steady upward trend from 3.87 in April 2022 to a peak of 5.06 by December 2023, before stabilizing between 4.47 and 4.94. This correlates with a reduction in the average inventory processing period, which declined from 94 days to a low of 72 days in December 2023, ultimately settling around 74 days by September 2026. This suggests enhanced efficiency in managing stock levels and accelerating product throughput.
Receivables and Collection Efficiency
Receivables turnover showed a gradual decline from its peak of 5.76 in October 2022 to 4.92 by September 2026. Consequently, the average receivable collection period expanded from a low of 63 days in October 2022 to 74 days by the end of the period. This trend indicates a slight slowing in the conversion of credit sales into cash.
Payables and Working Capital Dynamics
Payables turnover remained volatile, fluctuating between a high of 10.82 in July 2023 and a low of 7.27 in December 2025. The average payables payment period mirrored this instability, shifting from 46 days in April 2022 to 34 days in July 2023, before extending back to 40-50 days in later periods. Meanwhile, working capital turnover experienced a sharp peak of 10.13 in April 2023, followed by a general downward trend and significant fluctuation, reaching a low of 3.30 in December 2025, suggesting varying levels of efficiency in utilizing net current assets to drive revenue.
Operating and Cash Conversion Cycles
The operating cycle contracted from 164 days in April 2022 to approximately 148 days by September 2026, driven primarily by the gains in inventory processing. The cash conversion cycle (CCC) followed a similar trajectory, decreasing from 118 days to a low of 97 days in December 2022 and December 2024. However, a gradual increase in the CCC is observed toward the end of the period, rising to 108 days by September 2026, reflecting the combined impact of slower receivable collections and fluctuations in payables management.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Inventory Turnover

Thermo Fisher Scientific Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Cost of revenues 7,006 7,112 6,575 7,204 6,539 6,446 6,129 6,573 6,270 6,194 6,140 6,493 6,258 6,436 6,570 6,844 6,375 6,371 6,354
Inventories 5,643 5,627 5,496 5,425 5,745 5,559 5,224 4,978 5,430 5,198 5,133 5,088 5,404 5,655 5,664 5,634 5,722 5,668 5,483
Short-term Activity Ratio
Inventory turnover1 4.94 4.87 4.87 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.27 3.58 3.65 3.68 3.65 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96
Amgen Inc. 1.77 1.87 1.91 1.93 1.92 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48
Bristol-Myers Squibb Co. 5.69 5.36 5.20 5.18 5.31 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55
Danaher Corp. 3.38 3.20 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Eli Lilly & Co. 0.78 0.79 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Gilead Sciences Inc. 3.28 3.18 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Johnson & Johnson 2.10 2.08 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Merck & Co. Inc. 3.09 2.90 2.65 2.46 2.27 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74
Pfizer Inc. 1.69 1.72 1.57 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Regeneron Pharmaceuticals Inc. 0.83 0.76 0.74 0.66 0.64 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27
Vertex Pharmaceuticals Inc. 0.83 1.00 0.95 0.98 0.99 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Inventory turnover = (Cost of revenuesQ3 2026 + Cost of revenuesQ2 2026 + Cost of revenuesQ1 2026 + Cost of revenuesQ4 2025) ÷ Inventories
= (7,006 + 7,112 + 6,575 + 7,204) ÷ 5,643 = 4.94

2 Click competitor name to see calculations.


The inventory turnover ratio demonstrates a general upward trajectory over the analyzed period, indicating an improvement in the efficiency of inventory management and the speed at which stock is converted into revenue.

Initial Efficiency Gains (April 2022 – December 2023)
A sustained increase in inventory turnover is observed, rising from a low of 3.87 to a peak of 5.06. This period is characterized by a systematic improvement in asset utilization, as the cost of revenues remained relatively stable while inventory levels were gradually optimized, reaching a period low of 5,088 million US$ by the end of 2023.
Mid-Term Volatility (March 2024 – June 2025)
The ratio experienced a moderate decline, descending to 4.47 by June 2025. This downturn coincides with a buildup of inventory, which climbed to 5,745 million US$. The decrease in the turnover ratio during this phase suggests a temporary misalignment between inventory procurement and the cost of revenues, leading to slower stock rotation.
Recovery and Stabilization (September 2025 – September 2026)
An upward recovery is noted in the final segments of the period, with the ratio stabilizing between 4.85 and 4.94. This recovery was supported by a significant increase in cost of revenues, which peaked at 7,112 million US$ in June 2026, effectively increasing the velocity of inventory movement despite inventory levels remaining elevated around 5,600 million US$.

Overall, the operating activity related to inventory shows a marked improvement in efficiency compared to the early 2022 baseline. The ratio has established a higher floor, consistently remaining above 4.40 from 2023 onward, reflecting a more aggressive or efficient cycle of inventory liquidation.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Receivables Turnover

Thermo Fisher Scientific Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Revenues 12,137 11,994 11,005 12,215 11,122 10,855 10,364 11,395 10,598 10,541 10,345 10,886 10,574 10,687 10,710 11,450 10,677 10,970 11,818
Accounts receivable, less allowances 9,625 9,451 9,204 8,900 8,911 8,594 8,455 8,191 8,255 7,943 7,931 8,221 8,370 8,019 7,922 8,115 7,671 7,745 7,889
Short-term Activity Ratio
Receivables turnover1 4.92 4.90 4.91 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.89 4.66 5.03 4.86 4.67 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29
Amgen Inc. 3.57 3.55 3.88 3.67 4.06 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81
Danaher Corp. 6.21 6.33 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Eli Lilly & Co. 3.91 3.97 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Gilead Sciences Inc. 6.14 5.90 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Johnson & Johnson 5.23 5.14 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Merck & Co. Inc. 5.29 5.30 5.39 5.52 5.30 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49
Pfizer Inc. 4.48 5.10 5.03 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Regeneron Pharmaceuticals Inc. 2.23 2.37 2.60 2.50 2.51 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41
Vertex Pharmaceuticals Inc. 5.60 5.90 6.12 5.85 6.02 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Receivables turnover = (RevenuesQ3 2026 + RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025) ÷ Accounts receivable, less allowances
= (12,137 + 11,994 + 11,005 + 12,215) ÷ 9,625 = 4.92

2 Click competitor name to see calculations.


An analysis of the receivables turnover ratio indicates a gradual decline in collection efficiency over the observed period. While the ratio experienced an initial increase and a peak in late 2022, a sustained downward trend emerged throughout 2025 and 2026, suggesting a lengthening of the cash conversion cycle regarding customer payments.

Revenue Trends
Quarterly revenues remained relatively stable for the majority of the period, generally oscillating between 10.3 billion and 11.4 billion. A moderate growth phase is observed starting in late 2025, with revenues peaking at 12.2 billion in December 2025 and maintaining levels above 11.9 billion through September 2026.
Accounts Receivable Growth
A consistent upward trajectory in accounts receivable, less allowances, is evident. The balance increased from 7.89 billion in April 2022 to 9.63 billion by September 2026. This steady increase in outstanding receivables occurred even during periods where revenue remained flat, indicating that the growth in receivables outpaced the growth in sales.
Receivables Turnover Performance
The receivables turnover ratio peaked at 5.76 in October 2022, marking the period of highest collection efficiency. Following this peak, the ratio fluctuated between 5.0 and 5.5 throughout 2023 and 2024. A more pronounced decline began in 2025, with the ratio falling below 5.0 and stabilizing between 4.90 and 4.92 during 2026. This downward shift reflects a decrease in the frequency with which the average accounts receivable balance is collected during each quarter.
Operational Insight
The divergence between the rising accounts receivable balance and the declining turnover ratio suggests that the company is taking longer to collect payments from its customers. The transition from a peak ratio of 5.76 to a stabilized level of approximately 4.92 indicates a reduction in the velocity of receivables turnover, which may impact short-term liquidity if the trend continues without a corresponding increase in revenue growth.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Payables Turnover

Thermo Fisher Scientific Inc., payables turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Cost of revenues 7,006 7,112 6,575 7,204 6,539 6,446 6,129 6,573 6,270 6,194 6,140 6,493 6,258 6,436 6,570 6,844 6,375 6,371 6,354
Accounts payable 3,087 3,268 3,344 3,622 3,120 2,980 3,049 3,079 2,606 2,547 2,555 2,872 2,508 2,423 2,798 3,381 2,471 2,586 2,667
Short-term Activity Ratio
Payables turnover1 9.04 8.39 8.00 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 3.84 4.05 4.02 5.09 4.29 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65
Bristol-Myers Squibb Co. 3.33 3.53 3.38 3.90 3.42 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25
Danaher Corp. 6.09 5.72 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Eli Lilly & Co. 2.44 2.16 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Gilead Sciences Inc. 6.66 9.22 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Johnson & Johnson 3.46 3.41 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Merck & Co. Inc. 3.78 4.70 4.44 3.72 3.53 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25
Pfizer Inc. 4.16 3.73 3.72 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Regeneron Pharmaceuticals Inc. 2.11 2.03 2.24 2.24 2.30 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39
Vertex Pharmaceuticals Inc. 3.97 4.10 3.44 3.58 3.83 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Payables turnover = (Cost of revenuesQ3 2026 + Cost of revenuesQ2 2026 + Cost of revenuesQ1 2026 + Cost of revenuesQ4 2025) ÷ Accounts payable
= (7,006 + 7,112 + 6,575 + 7,204) ÷ 3,087 = 9.04

2 Click competitor name to see calculations.


The analysis of payables turnover from April 2022 through September 2026 reveals a period of initial volatility followed by a gradual decline and subsequent stabilization. The turnover ratio, which measures the frequency with which a company pays its suppliers, experienced significant fluctuations between 2022 and 2023 before trending toward a lower average in the later periods.

Payables Turnover Volatility and Trends
A high degree of variance is observed in the first half of the analyzed period. The ratio peaked at 10.82 in July 2023, indicating a rapid cycle of supplier payments. However, a subsequent downward trend emerged, with the ratio reaching its lowest point of 7.27 by December 2025. This decrease suggests a transition toward slower payment cycles or an extension of credit terms obtained from vendors.
Correlation Between Cost of Revenues and Payables
Cost of revenues remained relatively stable between $6.1 billion and $6.6 billion for much of the period, with notable increases appearing in late 2025 and mid-2026, peaking at $7.2 billion in December 2025. The payables turnover ratio typically declined when accounts payable grew disproportionately to the cost of revenues. For instance, in December 2025, the simultaneous peak in cost of revenues and accounts payable resulted in the period's minimum turnover ratio, indicating that the growth in liabilities outpaced the growth in operational costs.
Accounts Payable Management
Accounts payable balances showed a general upward trajectory, rising from $2.67 billion in April 2022 to a peak of $3.62 billion in December 2025. The increase in the average balance of payables is the primary driver behind the compression of the turnover ratio. By the end of the observed period in September 2026, the ratio recovered to 9.04, coinciding with a reduction in accounts payable to $3.09 billion, suggesting a correction in liability levels or a strategic acceleration of payments.

Overall, the data indicates a strategic shift in working capital management. The movement from higher turnover rates in 2023 to lower rates in 2024 and 2025 reflects an increase in the average time taken to settle obligations with suppliers, which typically serves to preserve operational liquidity.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Working Capital Turnover

Thermo Fisher Scientific Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data (US$ in millions)
Current assets 25,615 23,365 22,316 28,707 22,295 24,584 23,378 22,137 23,783 25,476 23,640 24,589 23,092 19,995 20,209 25,229 19,299 18,100 18,776
Less: Current liabilities 14,170 15,069 14,621 15,189 14,888 12,718 13,174 13,332 14,601 14,772 13,937 14,012 14,158 14,112 15,884 17,010 11,118 10,997 12,070
Working capital 11,445 8,296 7,695 13,518 7,407 11,866 10,204 8,805 9,182 10,704 9,703 10,577 8,934 5,883 4,325 8,219 8,181 7,103 6,706
 
Revenues 12,137 11,994 11,005 12,215 11,122 10,855 10,364 11,395 10,598 10,541 10,345 10,886 10,574 10,687 10,710 11,450 10,677 10,970 11,818
Short-term Activity Ratio
Working capital turnover1 4.14 5.59 5.87 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. — — — — — — — — — — — — — — — — — — —
Amgen Inc. 3.32 3.83 5.44 9.85 5.66 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34
Bristol-Myers Squibb Co. 4.40 4.81 5.84 7.83 6.20 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24
Danaher Corp. 4.46 4.76 3.83 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Eli Lilly & Co. 4.73 4.71 3.97 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 — 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Gilead Sciences Inc. 6.76 10.20 3.19 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Johnson & Johnson 111.11 20.07 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 — 4.88 5.02 5.57
Merck & Co. Inc. 6.64 7.44 8.15 4.28 3.39 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09
Pfizer Inc. 4.79 7.31 7.47 10.58 6.08 10.68 6.64 8.64 5,036.00 — 29.17 — 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Regeneron Pharmaceuticals Inc. 1.16 1.20 1.14 1.05 1.05 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46
Vertex Pharmaceuticals Inc. 1.94 1.46 1.56 1.64 1.92 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Working capital turnover = (RevenuesQ3 2026 + RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025) ÷ Working capital
= (12,137 + 11,994 + 11,005 + 12,215) ÷ 11,445 = 4.14

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a period of significant volatility in working capital management relative to revenue generation. While revenues remained relatively stable over the observed period, fluctuations in working capital levels led to substantial variances in the working capital turnover ratio, indicating inconsistent efficiency in utilizing short-term assets and liabilities to generate sales.

Revenue Performance
Quarterly revenues exhibited a high degree of stability, generally fluctuating between 10.3 billion and 12.2 billion US dollars. A slight upward trajectory is observed toward the end of the period, with values reaching a peak of 12.2 billion US dollars in December 2025 and maintaining levels above 12 billion US dollars into late 2026.
Working Capital Volatility
Working capital experienced extreme variance, ranging from a low of 4.3 billion US dollars in April 2023 to a high of 13.5 billion US dollars in December 2025. This instability suggests periodic shifts in current asset and liability compositions, which directly influenced the efficiency ratios.
Working Capital Turnover Trends
The turnover ratio demonstrates three distinct phases. Initially, the ratio remained stable between 5.40 and 6.13 throughout 2022. A significant anomaly occurred in April 2023, where the ratio peaked at 10.13, coinciding with the lowest recorded working capital levels. Subsequently, a downward trend prevailed through 2024 and early 2025, with the ratio frequently dropping below 4.50 as working capital increased.
Operational Efficiency Insights
The inverse relationship between working capital and the turnover ratio is evident. The sharp decline in the ratio from 10.13 in April 2023 to 3.30 in December 2025 indicates a decrease in the efficiency of working capital utilization. The recurrent fluctuations observed in 2025 and 2026, where the ratio swung between 3.30 and 5.87, suggest a lack of a steady-state operating cycle in short-term asset management.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Inventory Processing Period

Thermo Fisher Scientific Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data
Inventory turnover 4.94 4.87 4.87 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Short-term Activity Ratio (no. days)
Average inventory processing period1 74 75 75 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 112 102 100 99 100 107 98 90 89 75 75 73 77 85 81 75 66 73 74
Amgen Inc. 206 195 191 189 190 194 195 199 209 257 321 411 259 265 279 281 272 260 247
Bristol-Myers Squibb Co. 64 68 70 70 69 70 69 67 102 98 99 91 84 83 93 84 76 79 80
Danaher Corp. 108 114 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Eli Lilly & Co. 469 463 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Gilead Sciences Inc. 111 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Johnson & Johnson 174 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Merck & Co. Inc. 118 126 138 148 160 162 150 147 149 153 151 144 139 137 134 124 118 119 133
Pfizer Inc. 216 212 232 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Regeneron Pharmaceuticals Inc. 439 479 491 556 571 570 582 572 573 562 553 519 508 532 549 562 440 379 287
Vertex Pharmaceuticals Inc. 437 365 384 373 369 345 320 287 267 238 222 214 213 192 177 156 136 135 129

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 4.94 = 74

2 Click competitor name to see calculations.


An analysis of the operational activity ratios reveals a period of significant improvement in inventory management efficiency from April 2022 through December 2023, followed by a phase of stabilization spanning 2024 to 2026. The data indicates a consistent effort to accelerate the movement of goods, resulting in a lower capital commitment to inventory.

Inventory Turnover Trends
The inventory turnover ratio demonstrated a steady upward trajectory in the initial phase, rising from 3.87 in April 2022 to a peak of 5.06 by December 2023. From March 2024 through September 2026, the ratio remained relatively stable, fluctuating within a narrow range between 4.47 and 5.06, and concluding the period at 4.94. This progression signifies a sustained increase in the frequency of inventory replacement.
Average Inventory Processing Period
A notable reduction in the average inventory processing period is observed, with the duration falling from 94 days in April 2022 to a low of 72 days by December 2023. Following this period of optimization, the processing time entered a stabilization phase, oscillating between 72 and 82 days. The period ended at 74 days in September 2026, representing a net reduction of 20 days compared to the start of the analysis.
Operational Efficiency and Correlation
There is a clear inverse correlation between the turnover ratio and the processing period. The most aggressive efficiency gains occurred between April 2022 and December 2023, where the processing period decreased by approximately 23%. The subsequent plateauing of these metrics suggests that the organization reached an operational equilibrium in its supply chain and inventory holding strategy during the 2024-2026 timeframe.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Receivable Collection Period

Thermo Fisher Scientific Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data
Receivables turnover 4.92 4.90 4.91 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Short-term Activity Ratio (no. days)
Average receivable collection period1 74 74 74 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 75 78 73 75 78 79 79 71 75 78 80 75 76 75 74 71 68 72 69
Amgen Inc. 102 103 94 99 90 95 91 77 86 86 88 99 88 84 84 82 79 79 76
Danaher Corp. 59 58 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Eli Lilly & Co. 93 92 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Gilead Sciences Inc. 59 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Johnson & Johnson 70 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Merck & Co. Inc. 69 69 68 66 69 68 62 58 66 68 68 63 64 69 66 58 59 62 66
Pfizer Inc. 81 72 73 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Regeneron Pharmaceuticals Inc. 164 154 140 146 146 144 144 160 161 155 146 158 156 148 151 160 148 132 107
Vertex Pharmaceuticals Inc. 65 62 60 62 61 61 59 53 60 58 64 58 58 60 61 59 58 58 59

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 4.92 = 74

2 Click competitor name to see calculations.


An analysis of the operating activity ratios reveals a gradual decline in receivables management efficiency over the period from April 2022 through September 2026. The data indicates a clear inverse correlation between the receivables turnover ratio and the average receivable collection period.

Receivables Turnover Trends
The receivables turnover ratio exhibited an initial upward trend, peaking at 5.76 on October 1, 2022. Following this peak, a general downward trajectory is observed. The ratio fluctuated between 5.53 and 5.13 throughout 2023 and 2024, eventually stabilizing between 4.90 and 4.92 during the first three quarters of 2026. This decline suggests a slowing rate at which receivables are converted into cash.
Average Receivable Collection Period Analysis
The average receivable collection period mirrored the turnover trend, reaching its most efficient point of 63 days on October 1, 2022. Subsequently, a consistent increase in the time required to collect outstanding payments is observed. The period returned to 70 days by September 30, 2023, and continued a steady climb throughout 2024 and 2025. By March 2026, the collection period reached a plateau of 74 days, which persisted through September 2026.
Operational Efficiency and Patterns
The transition from a minimum collection period of 63 days to a maximum of 74 days represents a lengthening of the cash conversion cycle. While the initial phase of the observed period showed an improvement in collection speed, the subsequent long-term trend indicates a deterioration in efficiency. The stabilization at 74 days in the final year suggests a shift in credit terms or customer payment behaviors compared to the higher efficiency levels seen in late 2022.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Operating Cycle

Thermo Fisher Scientific Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data
Average inventory processing period 74 75 75 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Average receivable collection period 74 74 74 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Short-term Activity Ratio
Operating cycle1 148 149 149 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 187 180 173 174 178 186 177 161 164 153 155 148 153 160 155 146 134 145 143
Amgen Inc. 308 298 285 288 280 289 286 276 295 343 409 510 347 349 363 363 351 339 323
Danaher Corp. 167 172 150 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Eli Lilly & Co. 562 555 521 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Gilead Sciences Inc. 170 177 173 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Johnson & Johnson 244 247 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Merck & Co. Inc. 187 195 206 214 229 230 212 205 215 221 219 207 203 206 200 182 177 181 199
Pfizer Inc. 297 284 305 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Regeneron Pharmaceuticals Inc. 603 633 631 702 717 714 726 732 734 717 699 677 664 680 700 722 588 511 394
Vertex Pharmaceuticals Inc. 502 427 444 435 430 406 379 340 327 296 286 272 271 252 238 215 194 193 188

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 74 + 74 = 148

2 Click competitor name to see calculations.


The operating cycle exhibits a general downward trend over the analyzed period, reflecting an improvement in the efficiency of the cash-to-cash conversion process. From a peak of 164 days in early 2022, the cycle contracted to a low of 142 days by late 2023 and early 2024, before stabilizing between 148 and 149 days through 2026.

Average Inventory Processing Period
A significant reduction in inventory holding time is observed during the first two years of the period. The processing period decreased from 94 days in April 2022 to 72 days by December 2023. Following this improvement, the metric entered a phase of moderate volatility, peaking at 82 days in June 2025 before receding to 74 days by September 2026. This suggests a period of optimization in inventory management followed by a stabilization phase.
Average Receivable Collection Period
The collection period remained relatively stable with a slight upward drift over the long term. After an initial dip to 63 days in October 2022, the period generally trended upward, moving from the 66-70 day range in 2023 to a consistent 74 days by 2026. This indicates a gradual extension in the time required to collect payments from customers, which partially offset the gains made in inventory processing efficiency.
Operating Cycle Synthesis
The overall operating cycle is primarily driven by the movements in inventory processing, as the fluctuations in the collection period were less pronounced. The most notable improvement occurred between April 2022 and December 2023, where the cycle shortened by 22 days. While a temporary increase occurred in mid-2025, reaching 156 days, the cycle ultimately stabilized near 148 days. The net result is a leaner operating cycle compared to the 2022 baseline, indicating a more efficient conversion of resources into liquid assets.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Payables Payment Period

Thermo Fisher Scientific Inc., average payables payment period calculation (quarterly data)

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data
Payables turnover 9.04 8.39 8.00 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Short-term Activity Ratio (no. days)
Average payables payment period1 40 43 46 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 95 90 91 72 85 89 70 54 61 73 60 69 70 64 73 90 69 72 78
Bristol-Myers Squibb Co. 110 103 108 94 107 140 104 94 106 120 117 111 97 108 114 109 96 107 112
Danaher Corp. 60 64 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Eli Lilly & Co. 149 169 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Gilead Sciences Inc. 55 40 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Johnson & Johnson 106 107 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Merck & Co. Inc. 96 78 82 98 103 95 92 98 86 83 81 89 80 80 84 89 71 75 86
Pfizer Inc. 88 98 98 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Regeneron Pharmaceuticals Inc. 173 180 163 163 158 129 129 146 94 110 137 122 106 116 136 138 98 91 68
Vertex Pharmaceuticals Inc. 92 89 106 102 95 102 105 98 98 85 96 106 117 115 107 103 44 73 66

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 9.04 = 40

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a fluctuating trend in the management of accounts payable from April 2022 through September 2026. The data indicates a cyclical pattern in how the organization manages its obligations to suppliers, characterized by periods of accelerated payment followed by phases of extended credit utilization.

Payables Turnover Dynamics
The payables turnover ratio exhibited significant volatility, reaching a peak of 10.82 in July 2023 before declining to a low of 7.27 by December 2025. The higher turnover rates observed in 2023 suggest a more rapid settlement of obligations, whereas the lower ratios observed in late 2024 and 2025 indicate a deceleration in the frequency of supplier payments.
Average Payables Payment Period Trends
The average time taken to settle payables moved in inverse correlation with the turnover ratio. A notable contraction in the payment cycle occurred throughout the first half of 2023, with the payment period dropping to a minimum of 34 days by July 1, 2023. This was followed by a steady expansion of the payment window over the subsequent two years, peaking at 50 days on December 31, 2025. By the third quarter of 2026, the period began to contract again, returning to 40 days by September 26, 2026.
Working Capital and Liquidity Observations
The extension of the average payment period from 34 days in mid-2023 to 50 days by late 2025 suggests a strategic shift toward preserving cash flow and maximizing the use of supplier credit. The subsequent reduction in the payment period throughout 2026 indicates a return to a more accelerated payment schedule, possibly reflecting changes in supplier terms or a shift in liquidity management priorities.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Cash Conversion Cycle

Thermo Fisher Scientific Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Sep 26, 2026 Jun 27, 2026 Mar 28, 2026 Dec 31, 2025 Sep 27, 2025 Jun 28, 2025 Mar 29, 2025 Dec 31, 2024 Sep 28, 2024 Jun 29, 2024 Mar 30, 2024 Dec 31, 2023 Sep 30, 2023 Jul 1, 2023 Apr 1, 2023 Dec 31, 2022 Oct 1, 2022 Jul 2, 2022 Apr 2, 2022
Selected Financial Data
Average inventory processing period 74 75 75 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Average receivable collection period 74 74 74 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Average payables payment period 40 43 46 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Short-term Activity Ratio
Cash conversion cycle1 108 106 103 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 213 208 194 216 195 200 216 222 234 270 349 441 277 285 290 273 282 267 245
Danaher Corp. 107 108 86 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75
Eli Lilly & Co. 413 386 373 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198
Gilead Sciences Inc. 115 137 135 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100
Johnson & Johnson 138 140 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80
Merck & Co. Inc. 91 117 124 116 126 135 120 107 129 138 138 118 123 126 116 93 106 106 113
Pfizer Inc. 209 186 207 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96
Regeneron Pharmaceuticals Inc. 430 453 468 539 559 585 597 586 640 607 562 555 558 564 564 584 490 420 326
Vertex Pharmaceuticals Inc. 410 338 338 333 335 304 274 242 229 211 190 166 154 137 131 112 150 120 122

Based on: 10-Q (reporting date: 2026-09-26), 10-Q (reporting date: 2026-06-27), 10-Q (reporting date: 2026-03-28), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-27), 10-Q (reporting date: 2025-06-28), 10-Q (reporting date: 2025-03-29), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-28), 10-Q (reporting date: 2024-06-29), 10-Q (reporting date: 2024-03-30), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02).

1 Q3 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 74 + 74 – 40 = 108

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a fluctuating but generally managed cash conversion cycle, characterized by periods of increased efficiency followed by moderate expansions in the working capital window.

Average Inventory Processing Period
A notable downward trend occurred from April 2022, where the period stood at 94 days, reaching a low of 72 days by December 2023. This indicates a significant improvement in inventory turnover during the first two years. From 2024 through September 2026, the period stabilized, fluctuating within a narrower range between 72 and 82 days, eventually settling at 74 days.
Average Receivable Collection Period
Receivable collections remained relatively consistent throughout the analyzed timeframe. After an initial decrease to 63 days in October 2022, the collection period gradually lengthened and stabilized. From March 2024 to September 2026, the period remained steady between 68 and 74 days, suggesting a consistent credit policy and predictable customer payment behavior.
Average Payables Payment Period
Payment terms exhibited the most volatility among the operating ratios. A period of contraction was observed between April 2022 (46 days) and July 2023 (34 days), followed by a trend of extension that peaked at 50 days in December 2025. The period then declined to 40 days by September 2026, indicating shifts in supplier payment strategies or changing credit terms.
Cash Conversion Cycle
The overall cash conversion cycle reflects the combined impact of the aforementioned components, ranging from a peak of 118 days in April 2022 to lows of 97 days in December 2022 and December 2024. The cycle demonstrates a cyclical pattern rather than a linear trend, ending at 108 days in September 2026. While the cycle remains substantial, there is a net reduction in the number of days required to convert resources into cash compared to the initial observation period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?